The global Semaglutide market is estimated to be valued at US$ 2.17 Billion in 2022 and is expected to exhibit a CAGR of 8.71% over the forecast period 2023-2030, as highlighted in a new report published by Coherent Market Insights.
Market Overview:
Semaglutide is an injectable glucagon-like peptide-1 (GLP-1) receptor agonist used for the treatment of type 2 diabetes and obesity. It helps in regulating blood sugar levels and promotes ... Read more
The semaglutide market is primarily driven by the growing prevalence of type 2 diabetes across the globe. Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist used for the management of type 2 diabetes, effectively reduces blood glucose levels and promotes weight loss. Approved for the treatment of both type 2 diabetes and obesity, semaglutide mimics the effects of naturally occurring GLP-1, a hormone that regulates blood sugar levels and appetite.
